To verify this mechanism in thyroid cancer, we constructed a KDM1A plasmid containing a K661A point mutation (i.e., a lysine-to-alanine mutation at lysine 661) to disrupt its demethylase activity. Here, MBD2 is linked to thyroid cancer.